ENHANCED DELIVERY OF GANCICLOVIR TO THE BRAIN THROUGH THE USE OF REDOX TARGETING

被引:43
作者
BREWSTER, ME [1 ]
RAGHAVAN, K [1 ]
POP, E [1 ]
BODOR, N [1 ]
机构
[1] UNIV FLORIDA, J HILLIS MILLER HLTH CTR, COLL PHARM, CTR DRUG DISCOVERY, GAINESVILLE, FL 32610 USA
关键词
D O I
10.1128/AAC.38.4.817
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Enhanced delivery of ganciclovir to the brain was demonstrated by a redox-based chemical delivery system. A ganciclovir monoester in which a 1-methyl-1,4-dihydronicotinate was covalently attached to one of the hydroxymethyl functions was prepared. The stability of the ganciclovir chemical delivery system (DHPG-CDS) was evaluated in aqueous buffers and organ homogenates. In vivo distribution studies in the rat indicated that while ganciclovir poorly penetrated into the central nervous system and was rapidly eliminated, DHPG-CDS provided for therapeutically relevant (2.7 muM) and sustained levels of the parent compound through 6 h. An analysis of the area under the concentration curve indicated that the chemical delivery system delivered five times more ganciclovir than that of the parent drug. The high levels in the brain and reduced levels in the blood gave a brain-to-blood drug concentration ratio of 2.54 for ganciclovir when delivered by the chemical delivery system, compared to a ratio of 0.063 when the parent drug was administered. These data suggest that DHPG-CDS. could be a useful adjunct for the treatment of cytomegalovirus encephalitis.
引用
收藏
页码:817 / 823
页数:7
相关论文
共 38 条
  • [11] Drew W L, 1988, Infect Dis Clin North Am, V2, P495
  • [12] GANCICLOVIR - A REVIEW OF ITS ANTIVIRAL ACTIVITY, PHARMACOKINETIC PROPERTIES AND THERAPEUTIC EFFICACY IN CYTOMEGALOVIRUS INFECTIONS
    FAULDS, D
    HEEL, RC
    [J]. DRUGS, 1990, 39 (04) : 597 - 638
  • [13] FIALA M, 1988, REV INFECT DIS, V10, P250
  • [14] 9-([2-HYDROXY-1-(HYDROXYMETHYL)ETHOXY]METHYL)GUANINE - A SELECTIVE INHIBITOR OF HERPES GROUP VIRUS-REPLICATION
    FIELD, AK
    DAVIES, ME
    DEWITT, C
    PERRY, HC
    LIOU, R
    GERMERSHAUSEN, J
    KARKAS, JD
    ASHTON, WT
    JOHNSTON, DBR
    TOLMAN, RL
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1983, 80 (13): : 4139 - 4143
  • [15] HUMAN PHARMACOKINETICS OF THE ANTIVIRAL DRUG DHPG
    FLETCHER, C
    SAWCHUK, R
    CHINNOCK, B
    DEMIRANDA, P
    BALFOUR, HH
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1986, 40 (03) : 281 - 286
  • [16] EVALUATION OF GANCICLOVIR FOR CYTOMEGALO-VIRUS DISEASE
    FLETCHER, CV
    BALFOUR, HH
    [J]. DICP-THE ANNALS OF PHARMACOTHERAPY, 1989, 23 (01): : 5 - 12
  • [17] OPTIMIZING DRUG DELIVERY TO BRAIN-TUMORS
    GREIG, NH
    [J]. CANCER TREATMENT REVIEWS, 1987, 14 (01) : 1 - 28
  • [18] CYTOMEGALOVIRUS ENCEPHALITIS IN ACQUIRED IMMUNODEFICIENCY SYNDROME
    HAWLEY, DA
    SCHAEFER, JF
    SCHULZ, DM
    MULLER, J
    [J]. AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1983, 80 (06) : 874 - 877
  • [19] JEFFRIES DJ, 1989, J ANTIMICROB CHEMOTH, V23, P1
  • [20] JENSEN E, 1991, ACTA PHARM NORDICA, V3, P243